The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs

Journal of Molecular Medicine

Volumn 85, Issue 9, 2007, Pages 961-970

  Neuss, Heiko ^a   Huang, Xiaohua ^a   Hetfeld, Bettina K J ^a   Deva, Rupal ^a   Henklein, Petra ^a   Nigam, Santosh ^a   Mall, Julian W ^a   Schwenk, Wolfgang ^a   Dubiel, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

COP9 signalosome; COX 2; Coxibs; Proteasome; Ubiquitin

Indexed keywords

CULLIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PARECOXIB; PROTEASOME; ROFECOXIB; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; VALDECOXIB;

ARTICLE; CELL LYSATE; CELL STIMULATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG CONFORMATION; DRUG PROTEIN BINDING; ENZYME DEGRADATION; ENZYME REGULATION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CULLIN PROTEINS; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; ISOXAZOLES; MULTIPROTEIN COMPLEXES; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 34548030442     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0197-y     Document Type: Article

References (38)

1. Gasparini G, Longo R, Sarmiento R, Morabito A (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4:605-615
2. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222-229
3. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63:728-734
4. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2005) COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol
5. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ (2005) Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65:664-670
6. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747
7. Loll PJ, Picot D, Garavito RM (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2:637-643
8. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 271:15810-15814
9. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091
10. Furberg CD (2006) The COX-2 inhibitors-an update. Am Heart J 152:197-199
11. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME (2000) Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 374:325-333
12. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275:33951-33956
13. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479
14. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9-20
15. Willems AR, Schwab M, Tyers M (2004) A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 1695:133-170
16. Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K, Colicelli J, Kato J, Naumann M, Segal D, Seeger M, Carr A, Glickman M, Chamovitz DA (2000) Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16:202-203
17. Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, Deshaies RJ (2002) Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298:608-611
18. Schwechheimer C, Serino G, Callis J, Crosby WL, Lyapina S, Deshaies RJ, Gray WM, Estelle M, Deng XW (2001) Interactions of the COP9 signalosome with the E3 ubiquitin ligase SCFTIRI in mediating auxin response. Science 292:1379-1382
19. Zhou C, Wee S, Rhee E, Naumann M, Dubiel W, Wolf DA (2003) Fission yeast COP9/signalosome suppresses cullin activity through recruitment of the deubiquitylating enzyme Ubp12p. Mol Cell 11:927-938
20. Hetfeld BK, Helfrich A, Kapelari B, Scheel H, Hofmann K, Guterman A, Glickman M, Schade R, Kloetzel PM, Dubiel W (2005) The zinc finger of the CSN-associated deubiquitinating enzyme USP15 is essential to rescue the E3 ligase Rbx1. Curr Biol 15:1217-1221
21. Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R, Dubiel W (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 22:1302-1312
22. Huang X, Hetfeld BK, Seifert U, Kahne T, Kloetzel PM, Naumann M, Bech-Otschir D, Dubiel W (2005) Consequences of COP9 signalosome and 26S proteasome interaction. Febs J 272:3909-3917
23. Peng Z, Shen Y, Feng S, Wang X, Chitteti BN, Vierstra RD, Deng XW (2003) Evidence for a physical association of the COP9 signalosome, the proteasome, and specific SCF E3 ligases in vivo. Curr Biol 13:R504-R505
24. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630-1639
25. Huang X, Seifert U, Salzmann U, Henklein P, Preissner R, Henke W, Sijts AJ, Kloetzel PM, Dubiel W (2002) The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. J Mol Biol 323:771-782
26. Hetfeld BKJ, Bech-Otschir D, Dubiel W (2005) Purification method of the COP9 signalosome from human erythrocytes, vol 398. Elsevier Academic, San Diego, London, pp 481-491
27. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K (2000) N-[[(5-methyl-3-phenylisoxazol-4- yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43:1661-1663
28. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R (2000) IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19:5517-5524
29. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 312:1206-1212
30. Berse M, Bounpheng M, Huang X, Christy B, Pollmann C, Dubiel W (2004) Ubiquitin-dependent Degradation of Id1 and Id3 is Mediated by the COP9 Signalosome. J Mol Biol 343:361-370
31. Goel A, Boland CR, Chauhan DP (2001) Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172:111-118
32. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363-398
33. Liu C, Powell KA, Mundt K, Wu L, Carr AM, Caspari T (2003) Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. Genes Dev 17:1130-1140
34. Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, Kisselev AF, Tanaka K, Nakatani Y (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357-367
35. Nateri AS, Riera-Sans L, Da Costa C, Behrens A (2004) The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303:1374-1378
36. Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, and Dixit VM (2004) Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 303:1371-1374
37. McMurray RW, Hardy KJ (2002) Cox-2 inhibitors: today and tomorrow. Am J Med Sci 323:181-189
38. Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB (2003) Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 63:870-877